AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ImmunityBio shares surge 10.80% after hours on FDA designations, positive trials, and 467% ANKTIVA sales growth.
ByAinvest
Friday, Nov 28, 2025 4:14 pm ET1min read
ImmunityBio Inc. surged 10.80% in after-hours trading, driven by FDA designations, promising clinical trial results for glioblastoma and non-Hodgkin lymphoma, and a 467% year-to-date sales increase for its bladder cancer therapy ANKTIVA. Recent news highlighted growing patient preference for immunotherapy due to fewer side effects, bolstering investor confidence in the company’s market position. Strong financial results, including $75M in sales and ongoing trial advancements, further fueled optimism about future growth prospects.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet